Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months
NCT ID: NCT02889497
Last Updated: 2016-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
20900 participants
INTERVENTIONAL
2016-09-30
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunity and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China
NCT03893747
Immunogenicity and Safety of Two Different Commercial EV71 Vaccines
NCT03873740
An Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine
NCT01507857
Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine
NCT01636245
Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine
NCT06146088
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
300 subjects receive the first batch vaccine
300 subjects will be randomly received the first batch vaccine
the first batch vaccine
300 subjects receive the second batch vaccine
300 subjects will be randomly received the second batch vaccine
the second batch vaccine
300 subjects receive the third batch vaccine
300 subjects will be randomly received the third batch vaccine
the third batch vaccine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
the first batch vaccine
the second batch vaccine
the third batch vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Providing the subjects' legal identity certificate (birth certificate , residence booklet or ID card) and vaccination certificate, legal guardians can provide legal identity proof (resident booklet or ID card) so that the doctor can determine the subject identity to complete recruitment program;
* The subjects' guardians are able to understand and sign the informed consent voluntary. Guardians have the ability to use the thermometer ,dividing ruler and can fill out the Diary card ,follow-up card according to requirements;
* Persist for a 24 months visit.If doubtful HFMD case happen,the subject's guardian should send the subject to the medical institutions at above the county level and report this case to the investigator.The subjects who participate immunogenicity observation group can receive sample collection including blood,throat swab or anal awab according to program requirements.
Exclusion Criteria
* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine;
* History of seizures,convulsions or twitching ;Family history of progressive neurological disease;
* Autoimmune disease or immunologic deficiency.Any prior administration of immunodepressant in last 6month;
* History of asthma,thyroid ablation,angioneurotic edema, diabetes mellitus or malignant tumour;
* Alienia,functional asplenia,or any condition that cause asplenia or splenectomy;
* Diagnosed coagulation abnormalities (such as clotting factor deficiency, coagulation disorders, platelet disorder) or significant bruising or blood clotting disorder;
* Any acute disease or chronic disease attack in last 7 days;
* Any prior administration of blood products in last 3 month;
* Any prior administration of attenuated live vaccine in last 15 days , subunit or inactivated vaccines in last 7 days;
* Fever before vaccination, axillary temperature ﹥37.0℃;
* Attend Other vaccine or drug clinical trials concurrent in 6 months;
* Any condition that in the opinion of the investigator。
* Newly HFMD diagnosed patients after been enrolled;
* Any condition that in the opinion of the investigator or ethics committee think should be eliminated.
6 Months
71 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Chaoyang District Centre for Disease Control and Prevention
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
cycdc2016-6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.